IL-13 blocker dupilumab appears to improve survival in COVID-19
Treatment with dupilumab appears to improve survival rates for patients with moderate to severe COVID-19. Researchers reported these findings on August 16, 2022 in Open Forum of Infectious Diseases. “Our clinical trial suggests that treatment with the anti-allergy medicine dupilumab may decrease deaths due to COVID-19. UVA [University of Virginia] is the first to test this novel and promising approach […]
Recent Comments